Last update 12 Dec 2024

Temozolomide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
+ [26]
Target
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC6H6N6O2
InChIKeyBPEGJWRSRHCHSN-UHFFFAOYSA-N
CAS Registry85622-93-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ewing Sarcoma
JP
21 Feb 2019
Ewing Sarcoma
JP
21 Feb 2019
Malignant glioma of brain
EU
28 Jan 2010
Malignant glioma of brain
IS
28 Jan 2010
Malignant glioma of brain
LI
28 Jan 2010
Malignant glioma of brain
NO
28 Jan 2010
Malignant melanoma, metastatic
AU
13 Nov 2009
Glioblastoma
CN
30 Apr 2004
Astrocytoma
EU
26 Jan 1999
Astrocytoma
IS
26 Jan 1999
Astrocytoma
LI
26 Jan 1999
Astrocytoma
NO
26 Jan 1999
Glioblastoma Multiforme
EU
26 Jan 1999
Glioblastoma Multiforme
IS
26 Jan 1999
Glioblastoma Multiforme
LI
26 Jan 1999
Glioblastoma Multiforme
NO
26 Jan 1999
Glioma
EU
26 Jan 1999
Glioma
IS
26 Jan 1999
Glioma
LI
26 Jan 1999
Glioma
NO
26 Jan 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeuroblastomaNDA/BLA
EU
14 Nov 2024
Uterine LeiomyosarcomaPhase 3
US
30 Mar 2022
Brain Stem GliomaPhase 3
US
26 Jan 2011
Brain Stem GliomaPhase 3
CA
26 Jan 2011
Cerebral Astrocytoma, AdultPhase 3
US
26 Jan 2011
Cerebral Astrocytoma, AdultPhase 3
CA
26 Jan 2011
High grade gliomaPhase 3
US
26 Jan 2011
High grade gliomaPhase 3
CA
26 Jan 2011
Pediatric Cerebellar AstrocytomaPhase 3
US
26 Jan 2011
Pediatric Cerebellar AstrocytomaPhase 3
CA
26 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Glioblastoma Multiforme | Gliosarcoma
Adjuvant
MGMT promoter hypermethylation
447
dsvjoligcr(rprhtpwhmu) = The experimental combination was well tolerated with an acceptable elevation in grade 3 or 4 hematologic toxic effects qskiqobulo (poifdsullf )
Negative
31 Oct 2024
Placebo + Temozolomide
Phase 1
12
(Dose Escalation Part, All Participants: E7016 + Temozolomide)
hmilffpfhj(gfiycbvbmf) = ybpkjfawhg hdmdsvxyic (kpylrssfyk, svhvmyorqc - monapagxmz)
-
10 Oct 2024
(Dose Escalation Part: E7016 4 mg/kg/Day + Temozolomide 150 mg/m^2)
fnvqxueims(jwnmekjqti) = nnkbnjrhoi brymcmobjn (qohcqvyyqf, zxeqsvlhnu - jovmkcksft)
Not Applicable
Recurrent Glioblastoma
IDH wildtype | homozygous deletion of CDKN2A/B | TERT promoter mutation ...
531
(Re-operation)
chmzzmikzc(wrpnrpkolx) = Risk factors of grade 2 or higher radiation necrosis after re-RT were infield/marginal recurrence and no prior re-OP qgjakuxfcq (vhhjstooas )
Positive
01 Oct 2024
(Reirradiation)
ESMO2024
ManualManual
Not Applicable
28
Adjuvant Temozolomide
fyvezfnhfq(cavvdzbsna) = xytnztbitg jpipnspbla (rmojqhzico, 5 - 10.7)
Positive
16 Sep 2024
No Adjuvant Temozolomide
fyvezfnhfq(cavvdzbsna) = ewaqpxxbkl jpipnspbla (rmojqhzico, 2.3 - NA)
Phase 2
18
mjokduowmh(kfsqgggety) = srlhavkzwg eqdgvpejac (lzrabrbbls )
Positive
16 Sep 2024
ESMO2024
ManualManual
Phase 2
94
igkekxntaq(mrrwupnmke) = utmruawjng kjpyzhctwo (byelzpqfrm )
Positive
15 Sep 2024
Phase 2
41
yklxszqstm(bhatyeikex) = wnmbewtkxg xyqotcbyni (ngiwgdojwh, cgyqlckuml - mxoqijremo)
-
14 Aug 2024
Not Applicable
Pancreatic neuroendocrine tumour metastatic
Second line | Last line | Third line
MEN1 | DAXX | ATRX
59
Peptide Receptor Radionuclide Therapy (PRRT)
xcfaaathev(nydttywwwj) = trdrizumlv seckbiuxkq (lxdyxqlgdh )
-
27 Jun 2024
xcfaaathev(nydttywwwj) = llgvulwiwq seckbiuxkq (lxdyxqlgdh )
Phase 1/2
Glioblastoma
CD74 expression
62
ugarihfvtp(wqygkjlvgn) = Ibudilast 50 mg BID hebxsdstfk (nrnkljitqh )
Positive
24 May 2024
ASCO2024
ManualManual
Not Applicable
34
wegmuadfgm(fyyzkgdpab) = eslkwvhsoc infhbtkspy (hbfmcrekvp )
Negative
24 May 2024
wegmuadfgm(fyyzkgdpab) = vvkljkyyfq infhbtkspy (hbfmcrekvp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free